EuroBiotech: More Articles of Note

> Genmab posted detailed data from a phase 2a trial of its antibody-drug conjugate tisotumab vedotin in cervical cancer. The expansion cohort data confirm the positive efficacy seen in June’s top-line readout but suggest safety could hold the Seattle Genetics-partnered drug back. About half of the participants suffered from conjunctivitis, prompting Genmab to adopt a risk-management plan part way through the trial. Statement

> Ipsen reported updated data from a trial of cabometyx in first-line renal cell cancer. The readout suggests that, while cabometyx is effective in the indication, it may struggle to beat the efficacy of the combination of Opdivo and Yervoy. Cabometyx is yet to best Pfizer’s Sutent in terms of overall survival in the trial. Release

> NuCana built out its pitch to potential investors in its IPO with data from two trials. In a phase 1b in patients with recurrent ovarian cancer, NuCana’s lead candidate Acelarin in combination with carboplatin yielded an overall response of 39%. NuCana also posted interim data from a phase 1 trial of NUC-3373. Statement I More

> A phase 3 trial of Advicenne’s ADV7103 met its primary endpoint. The prolonged-release combination of potassium citrate and potassium bicarbonate improved outcomes in patients with distal renal tubular acidosis. Release

> TiGenix bolstered its U.S. team with the appointment of a head of medical department and associate director, clinical project. The new hires come on board at a time when TiGenix is stepping up its interest in the U.S. Statement

> AC Immune wrapped up enrollment in the low-dose cohort of its anti-Abeta vaccine trial. Release